Caplin Point Laboratories arm gets USFDA gesture for Neostigmine Methylsulfate Injection Kumar Jeetendra | April 22, 2021 New Delhi: Caplin Point Laboratories on Thursday said its subsidiary has received approval from the US health regulator for Neostigmine Methylsulfate Injection. Neostigmine Methylsulfate Injection is a cholinesterase inhibitor and is indicated for the reversal of the effects of non-depolariSing neuromuscular blocking agents (NMBAs) after surgery. “Caplin Steriles Ltd (Caplin) has been granted final approval …